Loading
A phase 3 trial of Pafolacianine in Lung cancer, run by On Target Laboratories, LLC, completed.
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting is a phase 3 interventional study registered as NCT04241315 by On Target Laboratories, LLC, with 112 participants recorded, started 2020-03-26 and reaching its primary completion in 2021-10-07. Interventions recorded: OTL38 for Injection, Near infrared camera imaging system. Conditions recorded: Lung Neoplasms, Lung Cancer.
Linked to the drug Pafolacianine because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pafolacianine and the tag pipeline.
Shares Pafolacianine and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/